Clinical Trial Update: Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE [Phase 4]

View source ↗

Summary

Clinical trial update for ICV AX 250 in MPS IIIB shows assessment of safety, tolerability, and efficacy in a Phase 4 study currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Type Iiib

Drugs mentioned

• AX 250

Snippet

Sponsor: Allievex Corporation | Conditions: MPS III B | Phase 4 | Status: ENROLLING_BY_INVITATION